欧洲非专利抗生素可持续获取的政策选择。
Policy options for sustainable access to off-patent antibiotics in Europe.
作者信息
Panteli Dimitra, Anderson Michael, Fieldman Thomas, Baraldi Enrico, Tängdén Thomas, Vogler Sabine, Årdal Christine, Mossialos Elias
机构信息
European Observatory on Health Systems and Policies, Brussels, Belgium.
Health Organisation, Policy, Economics (HOPE), Centre for Primary Care & Health Services Research, The University of Manchester, Manchester, UK.
出版信息
NPJ Antimicrob Resist. 2024 Nov 25;2(1):40. doi: 10.1038/s44259-024-00061-4.
Abstract
Securing sustainable access to existing antibiotics optimises agent choice for individual treatments and is crucial to curb antibiotic resistance. Access to antibiotics is often restricted in many countries, due to general market unavailability or episodic shortages. This article outlines key policy options to maintain availability of existing antibiotics and enhance antibiotic supply chain resilience focusing on the perspectives of European Union (EU) and European Economic Area (EEA) institutions and member states.
摘要
确保现有抗生素的可持续获取，可优化个体治疗的药物选择，对于遏制抗生素耐药性至关重要。在许多国家，由于市场普遍供应不足或偶尔出现短缺，抗生素的获取往往受到限制。本文从欧盟（EU）和欧洲经济区（EEA）机构及成员国的角度，概述了维持现有抗生素供应及增强抗生素供应链韧性的关键政策选择。
相似文献
1
Policy options for sustainable access to off-patent antibiotics in Europe.欧洲非专利抗生素可持续获取的政策选择。
NPJ Antimicrob Resist. 2024 Nov 25;2(1):40. doi: 10.1038/s44259-024-00061-4.
2
Differences in Patient Access to Newly Approved Antibacterial Drugs in EU/EEA Countries.欧盟/欧洲经济区国家患者获取新批准抗菌药物的差异。
Antibiotics (Basel). 2024 Nov 12;13(11):1077. doi: 10.3390/antibiotics13111077.
3
Towards further harmonisation? Migration policy in the European Union.迈向进一步协调？欧盟的移民政策。
Studi Emigr. 1994 Jun;31(114):210-37.
4
European Core Health Indicators - status and perspectives.欧洲核心健康指标——现状与展望
Arch Public Health. 2018 Aug 3;76:52. doi: 10.1186/s13690-018-0298-9. eCollection 2018.
5
Gonorrhoea and gonococcal antimicrobial resistance surveillance networks in the WHO European Region, including the independent countries of the former Soviet Union.世界卫生组织欧洲区域淋病和淋球菌抗菌药物耐药性监测网络，包括前苏联各独立国家。
Sex Transm Infect. 2013 Dec;89 Suppl 4:iv42-6. doi: 10.1136/sextrans-2012-050909.
6
Quality appraisal of antibiotic consumption in the community, European Union/European Economic Area, 2009 and 2017.2009 年和 2017 年欧盟/欧洲经济区社区抗生素使用情况的质量评估。
J Antimicrob Chemother. 2021 Jul 26;76(12 Suppl 2):ii60-ii67. doi: 10.1093/jac/dkab178.
7
Monitoring response to hepatitis B and C in EU/EEA: testing policies, availability of data on care cascade and chronic viral hepatitis-related mortality - results from two surveys (2016).监测欧盟/欧洲经济区乙型和丙型肝炎的反应：检测政策、护理级联数据的可用性以及慢性病毒性肝炎相关死亡率 - 两项调查（2016 年）的结果。
HIV Med. 2018 Feb;19 Suppl 1:11-15. doi: 10.1111/hiv.12599.
8
Trends in the hospital-sector consumption of the WHO AWaRe Reserve group antibiotics in EU/EEA countries and the United Kingdom, 2010 to 2018.2010 年至 2018 年欧盟/欧洲经济区国家和英国世卫组织 AWaRe 储备集团抗生素在医院部门的使用趋势。
Euro Surveill. 2022 Oct;27(41). doi: 10.2807/1560-7917.ES.2022.27.41.2101058.
9
The multifaceted nature of lack of access to antibiotics: types of shortage and specific causes, consequences, and solutions.抗生素可及性不足的多方面性质：短缺类型、具体原因、后果及解决办法。
Clin Microbiol Infect. 2025 Mar;31(3):333-338. doi: 10.1016/j.cmi.2024.11.012. Epub 2024 Nov 12.
10
European intensive care physicians' experience of infections due to antibiotic-resistant bacteria.欧洲重症监护医师对抗生素耐药菌感染的经验。
Antimicrob Resist Infect Control. 2020 Jan 2;9(1):1. doi: 10.1186/s13756-019-0662-8. eCollection 2020.
本文引用的文献
1
Implementing an EU pull incentive for antimicrobial innovation and access: blueprint for action.实施欧盟拉动抗菌药物创新和获取的激励措施：行动计划蓝图。
Lancet Microbe. 2024 Oct;5(10):100886. doi: 10.1016/S2666-5247(24)00109-5. Epub 2024 Jun 14.
2
Tackling medicine shortages during and after the COVID-19 pandemic: Compilation of governmental policy measures and developments in 38 countries.应对 COVID-19 大流行期间和之后的药品短缺问题：38 个国家政府政策措施和进展汇编。
Health Policy. 2024 May;143:105030. doi: 10.1016/j.healthpol.2024.105030. Epub 2024 Feb 24.
3
A national antimicrobial guide with local, customizable versions: how is it used? A two-year analysis.一份具有本地可定制版本的国家抗菌指南：它是如何使用的？一项为期两年的分析。
JAC Antimicrob Resist. 2023 Dec 21;5(6):dlad136. doi: 10.1093/jacamr/dlad136. eCollection 2023 Dec.
4
Challenges and opportunities for incentivising antibiotic research and development in Europe.欧洲激励抗生素研发面临的挑战与机遇。
Lancet Reg Health Eur. 2023 Jul 26;33:100705. doi: 10.1016/j.lanepe.2023.100705. eCollection 2023 Oct.
5
Estimating the impact of COVID-19 vaccine inequities: a modeling study.估算 COVID-19 疫苗分配不均的影响：一项建模研究。
Nat Commun. 2023 Jun 6;14(1):3272. doi: 10.1038/s41467-023-39098-w.
6
The launch of the EU Health Emergency Preparedness and Response Authority (HERA): Improving global pandemic preparedness?欧盟卫生应急准备和反应管理局（HERA）的启动：提高全球大流行病防范能力？
Health Policy. 2023 Jul;133:104844. doi: 10.1016/j.healthpol.2023.104844. Epub 2023 May 27.
7
Correlation between Antimicrobial Resistance and the Hospital-Wide Diverse Use of Broad-Spectrum Antibiotics by the Antimicrobial Stewardship Program in Japan.日本抗菌药物管理计划中抗菌药物耐药性与全院范围内广泛使用广谱抗生素之间的相关性。
Pharmaceutics. 2023 Feb 3;15(2):518. doi: 10.3390/pharmaceutics15020518.
8
Evaluation of the Performance of the Gulf Cooperation Council Centralised Regulatory Review Process: Strategies to Improve Product Authorisation Efficiency and Quality.评估海湾合作委员会集中监管审查程序的绩效：提高产品授权效率和质量的策略。
Pharmaceut Med. 2022 Aug;36(4):223-231. doi: 10.1007/s40290-022-00432-0. Epub 2022 Jun 29.
9
The overlooked pandemic of antimicrobial resistance.被忽视的抗微生物药物耐药性大流行。
Lancet. 2022 Feb 12;399(10325):606-607. doi: 10.1016/S0140-6736(22)00087-3. Epub 2022 Jan 19.
10
The EU Response to COVID-19: From Reactive Policies to Strategic Decision-Making.欧盟对新冠疫情的应对：从应急政策到战略决策
J Common Mark Stud. 2021 Sep;59(Suppl 1):56-68. doi: 10.1111/jcms.13259. Epub 2021 Nov 10.
Zotero 插件